Tolerability of leukotriene modifiers in asthma: A review of clinical experience

BioDrugs

Volumn 11, Issue 6, 1999, Pages 385-394

  Reques, Feliciano Gozalo ^a   Estrada Rodriguez, Juan L ^a  

^a HOSPITAL DE LEÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2 CYCLOPENTYL 2 [4 (2 QUINOLINYLMETHOXY)PHENYL]ACETIC ACID; 4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPYLTHIO]PHENYL] 4 HYDROXY 3 METHYLBUTYRIC ACID; ASTEMIZOLE; CALCIUM ANTAGONIST; CISAPRIDE; CYCLOSPORIN; CYTOCHROME P450 ISOENZYME; MONTELUKAST; PLACEBO; PRANLUKAST; QUIFLAPON; TERFENADINE; THEOPHYLLINE DERIVATIVE; TOMELUKAST; UNCLASSIFIED DRUG; VERLUKAST; ZAFIRLUKAST; ZILEUTON;

ADULT; ASTHMA; CHURG STRAUSS SYNDROME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERANCE; ELDERLY CARE; ENZYME ACTIVITY; ENZYME INHIBITION; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; HUMAN; LIVER CIRRHOSIS; LIVER FUNCTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; REVIEW; RISK BENEFIT ANALYSIS; STEROID THERAPY; TREATMENT INDICATION;

EID: 0033021192     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199911060-00003     Document Type: Review

References (53)

1. 1. Larsen JS, Jackson SK. Antileukotriene therapy for asthma. Am J Health Syst Pharm 1996; 53: 2821-30
2. 2. Chanarin N, Jhonston SL. Leukotrienes as a target in asthma therapy. Drugs 1994; 47 (1): 12-24
3. 3. Drazen J. Clinical studies with agents active on the 5-lipoxygenase pathway. Allergy 1995; 50 (22 Suppl.): 22S-6S
4. 4. Pauwells RA, Joos GF, Kips JC. Leukotrienes as therapeutic target in asthma. Allergy 1995; 50: 615-22
5. 5. Smith LJ. Leukotrienes in asthma. The potential therapeutic role of antileukotriene agents. Arch Intern Med 1996; 156: 2181-9
6. 6. Kane GC, Pollice M, Kim CJ, et al. A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings. J Allergy Clin Immunol 1996; 97: 646-54
7. 7. Liu MC, Dubė LM, Lancaster J. Acute and chronic effects of a 5-lipi'xygenase inhibitor in asthma: a 6 month randomized multicenter trial. J Allergy Clin Immunol 1996; 98: 859-71
8. 8. Israel E, Cohn J, Dubė L, et al. Effect of treatment with zileuton. a 5-lipoxygenase inhibitor, in patients with asthma: a randomized controlled trial. JAMA 1996; 275 (12): 931-6
9. 9. Schwartz HJ, Petty Th, Dubė LM. et al. A randomized controlled trial comparing zileuton with theophyline in moderate asthma. Arch Intern Med 1998; 158: 141-8
10. 10. Adkins JC, Brodgen RN. Zafirlukast: a review of its pharmacology and therapeutic potential in the management of asthma. Drugs 1998; 55 (1): 121-44
11. 11. Calhoun WJ, Lavins BJ, Glass M. Effect of Accolate (zafirlukast) on bronchoalveolar lavage fluid (bal) after segmental antigen bronchoprovocation (sbp) in patients with mild to moderate asthma. Am J Respir Crit Care Med 1995; 151 (4): A42
12. 12. Findlay SR, Barden JM, Easley CB, et al. Effect of the oral leukotriene antagonist, ICI 204,219, on antigen-induced bronchoconstriction in subjects with asthma. J Allergy Clin Immunol 1992; 89: 1040-5
13. 13. Dahlen S-E, Dahlen B, Eliasson E, et al. Inhibition of allergic bronchoconstriction in asthmatics by the leukotriene-antagonist ICI-204,219. In: Samuelsson B, editor. Advances in Prostaglandin Thromboxane and Leukotriene Research 1991. Prostaglandins and Related Compounds, 7th International Conference; 1990 May 28-Jun 1; Florence: 461-4
14. 14. Taylor IK, O'Shaughnessy KM, Fuller RW, et al. Effect of cysteinyl-leukotriene receptor antagonist ICI 204,219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 1991; 337: 690-4
15. 15. Nathan RA, Glass M, Snader L. Effects of 13 weeks of treatment with ICI 204, 219 (Accolate) or cromolyn sodium (Intal) in patients with mild to moderate asthma [abstract]. J Allergy Clin Immunol 1995; 95 (1): 388
16. 16. Bateman ED, Holgate ST, Rinks SM, et al. A multicentre study to assess the steroid-sparing potential of Accolate (zafïrlukast: 20mg bd). Allergy 1995; 50: P-0709
17. 17. Diamant Z, Timmers MC, van der Veen H, et al. The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo. J Allergy Clin Immunol 1995; 95: 42-51
18. 18. OShaughnessy TC, Georgiou P, Howland K, et al. The effect of pranlukast, an oral leukotriene antagonist, on leukotriene D4 challenge in normal volunteers. Thorax 1997; 52: 524-7
19. 19. Reiss TF, Sorkness CA, Stricker W, et al. Effects of montelukast (MK-0476), a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids. Thorax 1997; 52: 45-8
20. 20. Reiss TF, Chervinsky P, Dockhorn RJ, et al. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Arch Intern Med 1998; 158 (11): 1213-20
21. 21. Knorr B, Matz J, Bernstein JA, et al. Montelukast for chronic asthma in 6-to 14-year-old children: a randomized, double-blund trial. JAMA 1998; 279 (15): 1181-6
22. 22. Israel L, Rubin P, Kemp JP, et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild to moderate asthma. Ann Intern Med 1993; 119 (11): 1059-66
23. 23. O'Byrne PM, Israel E, Drazen JM. Antileukotrienes in the treatment of asthma. Ann Intern Med 1997; 127: 472-80
24. 24. Lau R. Drug interactions with zileuton. Lancet 1997; 349: 1479-80
25. 25. Wechsler ME, Garpestad E, Flier SR, et al. Pulmonary infiltrates, cosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafïrlukast. JAMA 1998; 279 (6): 455-7
26. 26. Kelloway JS. Zafïrlukast: The first leukotriene-receptor antagonist approved for the treatment of asthma. Ann Pharmacother 1997; 31 (9): 1012-21
27. 27. Fish JE, Kemp JP, Lockey RF, et al. Zafïrlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. Clin Ther 1997; 19 (4): 675-90
28. 28. Spector S, Miller CJ, Glass M. 13-week dose-response study with Accolale (zafïrlukast) in patients with mild to moderate asthma [abstract no. 105]. Allergy 1995; 50 Suppl.: 117
29. 29. Spector SL, Smith LJ, Glass M, et al. Effects of 6 weeks of therapy with oral doses of [CI 204,219, a leukotriene D4 re ceptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med 1994; 150: 618-23
30. 30. Nathan RA, Hanby LA, Kylstra JW, et al. Zafïrlukast improves symptoms of asthma and quality of life in asthmatic patients with moderate airflow obstruction [abstract no 2811]. Eur Respir J 1997; 10 (25 Suppl.): 438S
31. 31. Suissa S, Dennis R, Ernst P, et al. Effectiveness of the leukotriene receptor antagonist zafïrlukast for mild-to-modcrate asthma: a randomised, double-blind, placebo-controlled trial. Ann Intern Med 1997; 126 (3): 177-83
32. 32. Nayak A, Hanby LA, Bonuccelli CM, et al. Zafir̈lukasi improves nasal congestion and asthma symptoms in asthmatic patients [abstract]. Allergy Clin Immunol Int 1997; 9 (4 Suppl.): 241S
33. 33. Laitinen LA, Naya IP, Binks S, et al. Comparative efficacy of zafir̈lukast & low dose steroids in asthmatic on prn B2-agonist. Eur Respir J 1997; 10 (25 Suppl.): 419S-20S
34. 34. Nguyen MH, O'Connor JP, Kylstra JW, et al. Clinical outcomes of zafïrlukast treatment in patients with mild to moderate asthma. Allergy Clin Immunol Int 1997; 9 (4 Suppl.): 48S
35. 35. Masi AT, Hunder GG Lie JT, et al. The American College of Rheumatohology 1990 criteria for the classification of the Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990; 33: 1094-100
36. 36. Josefson D. Asthma drug linked with Churg-Strauss syndrome. BMJ 1997; 315: 330
37. 37. Wechsler ME, Drazen JM, Zafïrlukast and Churg-Strauss Syndrome, [letter]. JAMA 1998; 279 (24): 1950
38. 38. Churg A, Brallas M, Cronin SR, et al. Formes frustes of Churg-Strauss syndrome. Chest 1995; 108: 320-23
39. 39. McCarthy M. US warms on zafïrlukast [letter]. Lancet 1997; 350: 342
40. 40. Zeneca Pharmaceuticals. Zafïrlukast prescribing information. Delaware, USA. 1996
41. 41. Zeneca Pharmaceuticals. Zafïrlukast product monograph. Cheshire, UK. Aug. 1997
42. 42. Suttle AB, Birmingham BK, Vargo DL, et al. The pharmacokinetics of zafïrlukast and terfenadine after coadministration to healthy men [abstract]. J Clin Pharmacol 1997; 37: 870
43. 43. Reiss TF, Altman LC, Chervinsky P, et al. Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LID4) receptor antagonist, in patients with chronic asthma. J Allergy Clin Immunol 1996; 98: 528-34
44. 44. Knorr R, Reiss TF. Montelukast for children with asthma. [letter]. JAMA 1998; 280 (11): 967
45. 45. Barnes NC, de Jong B, Miyamoto T. Worldwide clinical experience wilh the first marketed leukotriene receptor antagonist. Chest 1997; 111 Suppl.: 52S-60S
46. 46. Barnes NC, Pujet J-C. Pranlukast, a novel leukotriene receptor antagonist: results of ihe first European, placebo controlled, multicentre clinical study in asthma. Thorax 1997; 52: 523-7
47. 47. Grossman J, Faiferuwan I, Duhb JW, et al. Results of the first US double-blind, placebo-controlled multicenter clinical trial in asthma wilh pranlukast: a novel leukotriene receptor antagonist. J Asthma 1997; 34 (4): 321-8
48. 48. Holgate ST, Anderson KD, Rodgers EM. Comparison of Accolate (zafïrlukast) with sodium cromoglycate in mild to moderate asthmatic patients. Allergy 1995; 50 Suppl.: P-0708
49. 49. Chung KF Kenelly JC, Summerton L, et al. Compliance with an oral asthma treatment: electronic monitoring of twice daily dosing with zafïrlukast [abstract #880]. Allergy Clin Immunol Int 1997; 9 (4Suppl.): 241S
50. 50. Ringdal N, Whitney JG, Summerton L. A comparison of patient preference for treatment with oral zafïrlukast or inhaled heclomethasone [abstract #2806]. Eur Respir J 1997; 10 (25 Suppl.): 437S
51. 5 1. O'Byrne PM. Treatment of mild asthma. Lancet 1997; 349: 818
52. 52. Laitinen LA, Zetterström O, Holgate ST, et al. Effects of Accolate (zafïrlukast 20mg bd) in permiting reduced therapy with inhaled steroids: a multicenter trial in patients with doses of inhaled steroid optimised between 800 and 2000 meg per day [abstract no. 710]. Allergy 1995; 50 (Suppl.): 320
53. 53. Virchow J, Hassall SM, Summerton L, et al. Reduction of asthma exacerbations with zafïrlukast in patients on inhaled corticosteroids [abstract no. 2717]. Eur Respir J 1997; 10 (25 Suppl.): 420S